Home＜ News & Events

News & Events

News Events Media Attention Partner News

 

2021.12
01

TOT BIOPHARM Announces NMPA Granted Marketing Approval for Pusintin® (TAB008, Bevacizumab Injection) in China

Dec.1, 2021, TOT BIOPHARM International Company Limited (TOT BIOPHARM, 1875.HK) announced its self-developed Pusintin® (TAB008, bevacizumab injection) has been officially granted approval by the National Medical Products Administration (“NMPA”) f…
2021.11
09

Groundbreaking Ceremony for Global R&D Center of TOT BIOPHARM Held!

On November 9th, the groundbreaking ceremony ofthe Global R&D Center of TOT BIOPHARM was successfully completed. Amongattendees of the ceremony including Mi Shen, member of the Standing Committeeof the CPC Suzhou Municipal Committee and Secretary of t
2021.05
31

TOT BIOPHARM’s Temozolomide Capsules (TOZ309) Approved for Marketing

On May 31, 2021, TOT BIOPHARM (Stock code:1875.HK) announced that its self-developed Temozolomide Capsules (TOZ309) obtained marketing approval from the National Medical Products Administration (NMPA) for the treatment of (1) newly diagnosed glioblastoma
2021.03
23

TOT BIOPHARM Announces 2020 Annual Results